Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 5, 2016, Pages 642-650

  Planchard, David ^a   Kim, Tae Min ^b   Mazieres, Julien ^c,d   Quoix, Elisabeth ^e   Riely, Gregory ^f,g   Barlesi, Fabrice ^h   Souquet, Pierre Jean ⁱ   Smit, Egbert F ^j   Groen, Harry J M ^k,l   Kelly, Ronan J ^m   Cho, B C ⁿ   Socinski, Mark A ^o   Pandite, Lini ^p   Nase, Christine ^q   Ma, Bo ^r   D'Amelio, Anthony ^s   Mookerjee, Bijoyesh ^s   Curtis, C Martin ^s   Johnson, Bruce E ^t  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Seoul National University Hospital   (South Korea)

^c SERVICE DE PNEUMOLOGIE   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF GRONINGEN   (Netherlands)

^l UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ Yonsei University College of Medicine   (South Korea)

^o UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^p Adaptimmune Ltd   (United Kingdom)

^q GLAXOSMITHKLINE   (United States)

^r Biothera   (United States)

^s NOVARTIS PHARMA AG   (Switzerland)

^t DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CREATININE; DABRAFENIB; ERLOTINIB; GLUTAMINE; TRAMETINIB; VALINE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR;

ACTINIC KERATOSIS; ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ALOPECIA; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; BACKACHE; BACTERIAL PERITONITIS; BASAL CELL CARCINOMA; BLISTER; BRAFV600E GENE; BRAIN HEMORRHAGE; CANCER PATIENT; CANCER STAGING; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CHILL; COHORT ANALYSIS; COLITIS; CONFUSION; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; GASTRITIS; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERKERATOSIS; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INTRACARDIAC THROMBOSIS; ISCHEMIC COLITIS; LEUKOCYTE COUNT; LEUKOPENIA; LIMB PAIN; LIP CARCINOMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MALNUTRITION; METASTASIS POTENTIAL; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL; PIGMENTED NEVUS; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RADIATION INJURY; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEBORRHEIC KERATOSIS; SIDE EFFECT; SKIN CARCINOMA; SKIN PAPILLOMA; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UVEITIS; VOMITING; WEIGHT REDUCTION; ADOLESCENT; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; GENETICS; MIDDLE AGED; MUTATION; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84964329499     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00077-2     Document Type: Article

References (36)

1. Siegel RL, Miller KD, Jemal A Cancer statistics, 2015. CA Cancer J Clin 2015, 65:5-29.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
3. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002, 62:7001-7003.
4. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
5. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007, 21:379-384.
6. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). Proc Soc Am Clin Oncol 2013, 31(15 suppl):8000.
7. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051.
8. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014, 311:1998-2006.
9. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011, 29:3574-3579.
10. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013, 19:4532-4540.
11. Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012, 7:e23-e24.
12. Gautschi O, Milia J, Cabarrou B, et al. Targeted Therapy for Patients with BRAF-mutant lung cancer: results from the European EURAF Cohort. J Thorac Oncol 2015, 10:1451-1457.
13. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
14. Rudin CM, Hong K, Streit M Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 2013, 8:e41-e42.
15. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015, 373:726-736.
16. King AJ, Arnone MR, Bleam MR, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One 2013, 8:e67583.
17. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
19. Green SJ, Dahlberg S Planned versus attained design in phase II clinical trials. Stat Med 1992, 11:853-862.
20. Brookmeyer R, Crowley J A confidence interval for the mean survival time. Biometrics 1982, 38:29-41.
21. Clopper CJ, Pearson ES The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
22. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
23. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
24. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
25. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384:665-673.
26. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 371:1867-1876.
27. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
28. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
29. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
30. Scagliotti G, von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 2015, 33:2667-2674.
31. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
32. V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014, 15:436-444.
33. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014, 371:1877-1888.
34. Villaruz LC, Socinski MA, Abberbock S, et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer 2015, 121:448-456.
35. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367:1694-1703.
36. Planchard D, Groen HJM, Kim TM, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). Proc Soc Am Clin Oncol 2015, 33(15 suppl):8006.